The unmet need to fight a growing global health care problem:
Proteinuria, CKD and ESRD

Trisaq is a pharmaceutical company dedicated to reversing the progression of chronic kidney disease ("CKD"). The company's products eliminate or modulate molecular targets that are responsible for the destruction of the kidney's podocytes and

for the deterioration of the kidneys' filtering function. These targets were newly discovered by the company's founders, and their central role in CKD pathogenesis is by now generally accepted. > More